điều trị loãng xương cho phụ nữ mãn kinh

X 2019 Tri Ph BON CON 003_27-06- guideline gia n ph cao trung NC NC NC sai NC quan NC quan 4* 3* 2* 1* 4* 3* 2* 1* t Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrin Society Clinical Practice Guideline x T socre -2.5 - -1.0 - score x x ph x x x x th th DEXA l ng Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrin Society Clinical Practice Guideline x x gia o Frax o Nguyen x o o Trung o Cao Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrin Society Clinical Practice Guideline x Nguy cao Nguy - 2.5 cao - 2.5 theo Frax Nguy trung - Nguy -1.0 - (-) (-) 3% 3% 20% 20% x Nguy x 20% H Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline x Ch a x x Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline sau x Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline trung x cao x 4* Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline x cao Biphosphonate: 4* o Zoledronate, alendronate, risedronate, ibandronate Denosumab: 4* 3* o Teriparatide, abaloparatide Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline Biphosphonate (4*) x Denosumab (4*) x Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline Denosumab (4*) Ng ng denosumab o o o o x giai nhanh holiday x x Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline sau 5-10 (1*) Teriparatide and Abaloparatide (PTH and x x (2*) Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline Teriparatide and Abaloparatide (3*) x Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline SERM (4*) Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline (3) biphosphonate,desonumab D 60 tim, ung th Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline (3*) Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline calcitonin (1) Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline Calcium vitamin D (1) x x Calcium o nguy x Vitamin D o nguy x Vitamin D + calcium o o nguy x x Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline 19% 5% Biphosphonate sau ng ng So o o x Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline AFF, nguy holidays x o o o x 80% nguy o Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline x x 2-4 T H A N K Y O U